HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment

被引：0
|
作者：
Altundag, Kadri [1 ]
机构：
[1] MKA Breast Canc Clin, TR-06800 Ankara, Turkey
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2019年 / 175卷 / 01期
关键词：
D O I：
10.1007/s10549-019-05151-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：261 / 261
页数：1
相关论文
共 50 条
  • [41] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Yang, Zheng-Jun
    Xin, Fei
    Chen, Zu-Jin
    Yu, Yue
    Wang, Xin
    Cao, Xu-Chen
    BMC CANCER, 2024, 24 (01)
  • [42] Methodology Used to Determine HER2 Status Correlates with Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer
    Cheng, Esther
    McIntire, Patrick
    D'Alfonso, Timothy
    Ginter, Paula
    LABORATORY INVESTIGATION, 2018, 98 : 54 - 54
  • [43] Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer
    Guarneri, Valentina
    Barbieri, Elena
    Piacentini, Federico
    Dieci, Maria Vittoria
    Omarini, Claudia
    Ficarra, Guido
    Bettelli, Stefania Raffaella
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
    Li, Aidan C.
    Zhao, Jing
    Zhao, Chao
    Ma, Zhongliang
    Hartage, Ramon
    Zhang, Yunxiang
    Li, Xiaoxian
    Parwani, Anil, V
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 321 - 329
  • [45] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
    Antolin, Silvia
    Garcia-Caballero, Lucia
    Reboredo, Cristina
    Molina Diaz, Aurea
    Mosquera, Joaquin
    Vazquez-Boquete, Angel
    Gallego, Rosalia
    Paz Santiago, Maria
    Concha, Angel
    Eva Perez, Maria
    Calvo, Lourdes
    Garcia-Caballero, Tomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients
    Lillemoe, T. J.
    Susnik, B.
    Grimm, E.
    Kang, S-H L.
    Swenson, K. K.
    Krueger, J. L.
    Finkelstein, M. J.
    Tsai, M. L.
    CANCER RESEARCH, 2017, 77
  • [47] Treatment of HER2 positive breast cancer patients
    Matos, Erika
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2012, 81 (03): : 236 - 245
  • [48] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy.
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    MODERN PATHOLOGY, 2018, 31 : 91 - 91
  • [49] HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome
    Bottosso, Michele
    Sandoval, Renata L.
    Verret, Benjamin
    Polidorio, Natalia
    Caron, Olivier
    Gennari, Alessandra
    Bychkovsky, Brittany L.
    Cahill, Sophie H.
    Achatz, Maria I.
    Guarneri, Valentina
    Andre, Fabrice
    Garber, Judy E.
    EUROPEAN JOURNAL OF CANCER, 2024, 211
  • [50] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
12345